Written by:
Dr. Sophie Reynolds

Dr. Sophie Reynolds is a board-certified medical doctor specializing in internal medicine. With over a decade of experience in patient care and medical writing

Tucanat 150 mg Tablet

Brand Name:   Tucanat
Molecule:   Tucatinib
Strength:   150 mg
Quantity:   60 Tablets
Form:   Tablet
Packaging Type:   Bottle
Manufacturer/Marketed By:   Natco Pharma
Country of Origin:   India

FAQ

What is Tucanat 150 mg used for?+
Tucanat 150 mg, containing the active ingredient tucatinib, is used in combination with other medications for the treatment of advanced breast cancer, particularly in patients with HER2-positive tumors.
How does Tucanat 150 mg work?+
Tucanat 150 mg works as a targeted anticancer drug by inhibiting the HER2 tyrosine kinase, which is overexpressed in some breast cancers, thereby slowing down tumor growth and proliferation.
What are the common side effects of Tucanat 150 mg?+
Common side effects of Tucanat 150 mg may include diarrhea, fatigue, elevated liver enzymes, and rash. It is essential to discuss any side effects with a healthcare provider.
Who should not take Tucanat 150 mg?+
Tucanat 150 mg should not be taken by individuals with known hypersensitivity to tucatinib or any of its components. Patients with severe liver impairment should also avoid its use.
Can Tucanat 150 mg be taken with other medications?+
Tucanat 150 mg may interact with other medications. It is essential to inform your healthcare provider about all medicines, supplements, and herbal products you are taking before starting tucatinib.

Related Products

Related Posts:

Ruxolitinib Tablets Receive FDA Approval for Hematologic Malignancies

The U.S. Food and Drug Administration (FDA) has approved Ruxolitinib tablets for the treatment of certain hematologic malignancies, marking another

READ MORE »
Tovorafenib Approved in Europe for Children with BRAF-Altered Low-Grade Glioma

n Medical Review: This article was reviewed by Dr. Sophie Reynolds on May 14, 2026.n n This marks an important

READ MORE »
FDA Approves Vepdegestrant for ER+/HER2–, ESR1-Mutated Breast Cancer: A New Targeted Option

Medical Review: This article was reviewed by Dr. Sophie Reynolds on May 6, 2026. Breast cancer treatment continues to evolve

READ MORE »
0 reviews
0
0
0
0
0

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.